Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Akero Therapeutics Stock Surges on Novo Nordisk Buyout
10:11am, Thursday, 09'th Oct 2025
Novo Nordisk A/S (NYSE:NVO) is down 1% to trade at $59 this morning, after news surfaced that the pharmaceutical concern has entered an agreement to purchase U.S.-based peer Akero Therapeutics Inc (NA
Novo Nordisk To Acquire Liver Disease Focused Akero Therapeutics For Around $5 Billion
09:10am, Thursday, 09'th Oct 2025
Novo Nordisk A/S (NYSE:NVO) agreed on Thursday to acquire Akero Therapeutics, Inc. (NASDAQ:AKRO) focused on metabolic diseases.
Novo Nordisk acquires Akero Therapeutics and its promising liver therapy for up to $5.2B
08:54am, Thursday, 09'th Oct 2025
Novo Nordisk (NYSE:NVO) announced it is acquiring Akero Therapeutics (NASDAQ: AKRO) for a total potential value of up to $5.2 billion, strengthening its pipeline in treatments for metabolic dysfunct
Akero Therapeutics Stock Soars on Novo Nordisk Deal.
07:31am, Thursday, 09'th Oct 2025
Novo said it would buy Akero for $54 a share in cash and an additional $6 if it gets U.S. approval of Efruxifermin - it's treatment for fatty liver disease.
Novo Nordisk is paying up to $5.2 billion for a San Francisco biotech working on liver disease
06:59am, Thursday, 09'th Oct 2025
Novo Nordisk, the Danish drugmaker behind Ozempic and other weight-loss drugs, said it's paying up to $5.2 billion to buy Akero Therapeutics, a biotech with a drug in a late-stage trial to treat a fat
Novo Nordisk To Buy Akero Therapeutics for $4.7 Billion
06:39am, Thursday, 09'th Oct 2025
Novo said the acquisition of would contribute to its strategy to develop medicines for people living with diabetes, obesity and their associated comorbidities.
Novo Nordisk buys Akero Therapeutics in the US
06:09am, Thursday, 09'th Oct 2025
Danish drugmaker Novo Nordisk said on Thursday it had agreed to buy United States based Akero Therapeutics, a clinical-stage company developing innovative treatments for patients with serious metaboli
Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion
06:01am, Thursday, 09'th Oct 2025
Shareholders to Receive $54 Per Share in Cash and CVR of $6 Per Share Advances Akero's Mission of Bringing Novel Therapies to Patients with High Unmet Medical Needs SOUTH SAN FRANCISCO, Calif., Oct.
Novo Nordisk to acquire Akero Therapeutics and its promising phase 3 FGF21 analogue to expand MASH portfolio
06:00am, Thursday, 09'th Oct 2025
Bagsværd, Denmark, 9 October, 2025 – Novo Nordisk today announced that it has entered into a definitive agreement to acquire Akero Therapeutics, Inc. (Akero), a publicly held clinical-stage company
Carolina Wealth Makes a Big $6 Million Bet on Novo Nordisk (NYSE: NVO)
02:40pm, Wednesday, 08'th Oct 2025
On October 07, 2025, Carolina Wealth Advisors, LLC disclosed a buy of Novo Nordisk A/S (NYSE: NVO) shares, an estimated $6.01 million trade based on the average price for Q3 2025.
Wall Street Breakfast Podcast: Deals Don't Wait 'Til November
06:52am, Tuesday, 07'th Oct 2025
Amazon (AMZN) launches Prime Big Deal Days, kicking off early holiday shopping with exclusive offers and increased competition from Target and Walmart. Novo Nordisk (NVO) cuts dozens of production job
Novo Nordisk: Oral Wegovy Nears FDA Decision As GLP-1 Momentum Builds
06:14am, Tuesday, 07'th Oct 2025
Novo Nordisk is well-positioned in the obesity drug market, with strong financials and anticipation for its oral Wegovy pill. NVO's first-half 2025 results showed robust growth, driven by obesity fran
Exclusive: Novo Nordisk cuts hit production line jobs at key US plant, posts show
01:03am, Tuesday, 07'th Oct 2025
Wegovy-maker Novo Nordisk has laid off dozens of employees at the largest U.S. manufacturing site for its blockbuster obesity and diabetes drugs, a Reuters review of LinkedIn posts showed, a signal of
US court rejects Novo Nordisk's challenge to Medicare drug pricing plan
04:41pm, Monday, 06'th Oct 2025
A federal appeals court on Monday rejected Novo Nordisk's challenge to the U.S. government's program that gives its Medicare health insurance plan the power to negotiate lower drug prices, the latest
Novo Nordisk: CagriSema Sets Potential Obesity Drug Development Comeback
12:26pm, Monday, 06'th Oct 2025
Downgrading Novo Nordisk from a "Strong Buy" rating to a "Buy" rating, whereby it may or may not be able to overcome competition in the obesity drug development space. Company faces competition from E
